32 research outputs found
ããŠã¹æ¥çš®æ³ããã³è¢å æäœæ³ã«ããå± æ®ºè±ããã®Toxoplasma gondiiã®æ€åºã«ã€ããŠ
Ninety five pigs suspicious of Toxoplasma-infection were selected from 18,867 ones killed at Isahaya City Slaughterhouse and used for the isolation of T. gondii with mouse inoculations of their hilar or hepatic lymph nodes and also for the microscopic detection of the parasite in the lymph nodes with direct fluorescent antibody technic. In the mouse inoculation method, Toxoplasma hemagglutination test was carried out with sera of mice killed 6 weeks after the inoculation of the lymph nodes into the mice. Further, T. gondii strains newly isolated were subinoculated into mice and hamsters to investigate their virulence. The isolation rate of T. gondii was 8/95 or 8.4%, while 33 of 95 (34.7%) were positive in hemagglutination test. Fluorescent antibody technic indicated a positive response in 19 of 95 pig lymph nodes (20.0%). Eight T. gondii strains were isolated and demonstrated a high virulence for mice and hamsters. In this paper, the methods used and the above mentioned results are stated in detail and discussed.é·åŽçè««æ©åžç«å± å Žã«1966幎12æãã1967幎3æãŸã§ã«æ¬å
¥ãããè±18,867é ãã,å± å Žç£å»åž«ã®ååã«ããéžæããããããœãã©ãºãçã®çãããç
å€è±(èºæ°Žè
«,èå£æ»æ,è
žå
è¡ãªã©)95é ã®èãŸãã¯èºéãªã³ãè
ºã®è¢å
æäœæ³(çŽæ¥æ³)ã«ããåè«æ€åº,ããŠã¹æ¥çš®æ³ã«ããåè«åé¢,ããã³æ¥çš®ããŠã¹ã®HAæäœäŸ¡ã枬å®ã,ãããã®æ瞟ãæ¯èŒæ€èšãã.ãŸãåé¢ãããæ ªã®æ¯æ§ã«ã€ããŠãRHæ ªãšæ¯èŒãæ€èšãã.1.ããŠã¹æ¥çš®æ³ã«ãããããœãã©ãºãåè«åé¢ã¯95äŸäž8äŸ(åè«åé¢ç8.4%)ã§,ããããæ é€åãæ€åºããã.åé¢8æ ªäž5æ ªã¯ç¶ä»£åæã«ãããŠã¯,ã·ã¹ãåãæ€åºããã.2.ããŠã¹æ¥çš®æ³ã«ããHAæäœäŸ¡éœæ§(256å以äžéœæ§)ã¯95äŸäž33(éœæ§ç34.7%)ã§ãã£ã.åè«åé¢8æ ªã¯ããããHAéœæ§ã§ãã£ã.3.è±ã®èãŸãã¯èºãªã³ãè
ºã®å²é¢ã¹ã¿ã³ãæšæ¬ã®,è¢å
æäœæ³(çŽæ¥æ³)ã«ãããããœãã©ãºãåè«ã®æ€åºçã¯95äŸäž19äŸ(æ€åºç20.0%)ã§ãã£ã.ãã®19äŸäž4äŸããããŠã¹æ¥çš®æ³ã«ããåè«ãåé¢ã§ãã.4.åé¢æ ªã®ããŠã¹ããã³ãã ã¹ã¿ãŒã«å¯Ÿããæ¯æ§ã¯RHæ ªãšåãçšåºŠããã匱æ¯ã§ãã£ã
å± å Žã®äœæž©å®€å ã«ãããToxoplasma gondiiã®çåæéã«é¢ããç 究
Examination was made of the survival period of Toxoplasma gondii in the low temperature rooms of a slaughterhouse. Materials for the examination were the mouse bodies themselves and the organs, such as the liver and brain, of mice infected with the RH or Beverley strain. These materials were stored in both of the refrigerating and the cold-storage rooms, then taken out of the rooms one after another at a short interval and examined on the existence of live Toxoplasma in them with the intraperitoneal inoculation into healthy mice. In the first experiment, it was revealed that the survival of the proliferative form of Toxoplasma in an infected mouse body was 8 days in the refrigerating room and 4 days in the cold-storage room, but a putrefactive sign was manifesting slowly in the mice stored more than 13 days in the refrigerating room and 6 days in the other. In the following experiment, the livers excised from RH-infected mice and the brains from Beverley-infected ones were stored only in the refrigerating room. It was recognized as the result that cysts were capable of survival for as long as 67 days and proliferative forms could survive for 11 days in the room. A control experiment was attempted on the resistance of T. gondii to -14â in a freezer and it was shown that both forms of this protozoa in the infected mouse organs could remain alive more than an hour but did not for 3 hours in a freezer of -14â. Temperatures in both rooms were continuously measured by auto-recording thermometers. In the refrigerating room, it was 0.47â in average and the cold-storage room always had 3 to 4â higher temperature than the refrigerating room.Toxoplasma gondiiã®äœæž©ã«å¯Ÿããæµææ§ã«ã€ããŠã®å ±åã¯å°ãªããªãããããããããã®ç 究ã§ã¯ãå®éšå®€å
ã®å·èµåº«ãŸãã¯ããªãŒã¶ãŒãªã©ã®ç²Ÿç¢ºã«èª¿ç¯ããã枩床æ¡ä»¶äžã«å®æœããããã®ã§ãããå± çèããã®å
èäžã«æœåšããæ¬åè«ãããã£ãšãéèŠãªæææºãšèŠãªãããŠããçŸåšã§ã¯ãå± å Žã®äœæž©å®€äžã§çèäžã®æ¬åè«ããã©ãçšã®æéçåãã€ã¥ããããç«åŠäžéèŠãªæå³ãæã€ããšã¯ãããŸã§ããªããäºå®ãå± å Žã®å·åŽå®€ãããã¯å·èµå®€ã®æž©åºŠã¯ãé »åã®æã®ééã倧éã®æž©ãã倧åç©èå¡ã®æ¬å
¥ãªã©ã®ãããçžåœãªå€åãåããããšãäºæž¬ãããå®éšå®€ã®å·èµåº«å
枩床æ¡ä»¶ãšã¯ããªãç°ãªããã®ã§ãããšèããããããæ¬ç 究ã¯ã以äžã®è¶£æšã«æ²¿ã£ãŠé·åŽåžå¶å± å Žå
ã®äœæž©å®€ãå©çšããT. gondiiã®å¢æ®åããã³ïŒåã®çåæéãæ€èšããã被æ€ææã¯ã倧åç©èå¡ãå
èãçšããããšãã§ããªãã£ãã®ã§ãRHããã³Beverleyæ ªææããŠã¹ããã³ãã®èåšã䜿çšãããã第1å®éšã§ã¯ãPHæ ªææããŠã¹èªäœãå·åŽå®€ããã³å·èµå®€ã«ä¿åããã以åŸãæ¯æ¥ãŸãã¯éæ¥ã«ä¿åããŠã¹äœãåãåºãããã®èããã³èŸä¹³å€ãå¥åžžããŠã¹è
¹è£å
æ¥çš®ãããã®ããŠã¹ããã®åè«æ€åºãè©Šã¿ããæ¥çš®ã30æ¥ä»¥å
ã«æ»äº¡ããããŠã¹ã¯å³æã«ããã以äžçåãããã®ã¯å± 殺ããŠããã®è
¹è£æ¶²ããã³è³äžã®åè«ã®æç¡ãé¡åŸ®é¡äžã«æ€èšããããã®æ瞟ã§ã¯ãããŠã¹äœå
ã®RHæ ªå¢æ®åã¯å·åŽå®€äžã§8æ¥éãå·èµå®€äžã§4æ¥éçåããããšãèªãããããããä¿åããŠã¹ã®è
¹è£å
èåšã®è
æãå·åŽå®€ã§ã¯13æ¥ã以éããããŸãå·èµå®€ã§ã¯6æ¥ãããèªããããããšããããã®æ瞟ã«ã¯ããŠã¹ã®è
æã圱é¿ãåãŒããŠããããšãæ³åããããå®éšäžã®å®€æž©ã¯ãå·åŽå®€ã§ã¯å¹³å0.9âãæé«2.5âãæäœ-1.1âãå·èµå®€ã§ã¯å¹³å4.2âãæé«äœå·Ÿã¯5.1ïœ3.2âã§ãã£ããã第2å®éšã§ã¯ãRHæ ªææããŠã¹èãšBeverleyæ ªææããŠã¹è³ãå·åŽå®€äžã«ä¿åããäžå®æéæ¯ã«åãåºããä¹³å€ãšããŠå¥åžžããŠã¹ã«æ¥çš®ãããæ¬å®éšã«ããããŠã¹èäžã®RHæ ªå¢æ®åã¯11æ¥éãããŠã¹ã®è³äžã®Beverleyæ ªååã¯å®ã«67æ¥éå·åŽå®€ã§çåããããšãå€æãããå®éšæéäžã®å·åŽå®€æž©åºŠã¯å¹³å0.47âãæé«äœå·Ÿã¯3.2ïœ-3.5âã«ãããã ã察ç
§å®éšãšããŠã-14âã®ããªãŒã¶ãŒã®äžã§ç¬¬2å®éšãšåäžææãçšããŠæ€æ»ãããããã®çµæãååãå¢æ®åãšãã1æéä¿åææäžã«çåããããšãèªãããã3æéææããã¯èšŒæã§ããªãã£ããã以äžã®å®éšã§ãå± å Žå·åŽå®€äžã§ååã¯67æ¥éãå¢æ®åã¯11æ¥éçåãããã€ãææåãä¿æããŠããããšãå€æãããã倧åç©èå¡ãèåšäžã§ã¯ãããé·æéçåããããšãæ³å®ããã
Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study
We (JMAAV [Japanese patients with MPO-ANCA-associated vasculitis] Study Group) performed a prospective, open-label, multi-center trial to evaluate the usefulness of severity-based treatment in Japanese patients with myeloperoxidase-anti-neutrophil cytoplasmic antibodies (MPO-ANCA)-associated vasculitis. Patients with MPO-ANCA-associated vasculitis received a severity-based regimen according to the appropriate protocol: low-dose corticosteroid and, if necessary, cyclophosphamide or azathioprine in patients with mild form; high-dose corticosteroid and cyclophosphamide in those with severe form; and the severe-form regimen plus plasmapheresis in those with the most severe form. We followed up the patients for 18 months. The primary end points were the induction of remission, death, and end-stage renal disease (ESRD). Fifty-two patients were registered, and 48 patients were enrolled in this study (mild form, n = 23; severe form, n = 23; most severe form, n = 2). Among the 47 patients who received the predefined therapies, 42 achieved remission within 6 months, 5 died, and 1 developed ESRD. Disease flared up in 8 of the 42 patients with remission during the 18-month follow-up period. The JMAAV trial is the first prospective trial for MPO-ANCA-associated vasculitis to be performed in Japan. The remission and death rates were comparable to those in several previous clinical trials performed in western counties. The regimen employed in this trial was tailor-made based on patientsâ disease severity and disease type, and it seems that standardization can be consistent with treatment choices made according to severity
A consideration regarding change of students after better class management using UDL: An attention to desirable self-esteem and better attitudes toward learning
It is needed to change from traditional teacher-oriented lessons to learning-oriented ones in order to enhance academic abilities of students and satisfy the learning needs of an individual student.
For finding an appropriate answer for it, our school has improved class management based on Universal Design for Learning proposed by an American educational institute, CAST 2008. The UDL recommends a flexible class design without making a barrier in front of a specific learner, and aims to foster active learners, while thinking about diversity. Regarding the introduction of a framework of UDL in a school between April 2020 and October 2021, it was confirmed that the students of the specific grade showed desirable self-esteem and better attitudes toward learning. The teachers of the grade, in particular, actively introduced the framework of UDL in class.
This thesis is introducing a class with the framework of UDL and considering the effects of it
å± å Žã®äœæž©å®€å ã«ãããToxoplasma gondiiã®çåæéã«é¢ããç 究
Examination was made of the survival period of Toxoplasma gondii in the low temperature rooms of a slaughterhouse. Materials for the examination were the mouse bodies themselves and the organs, such as the liver and brain, of mice infected with the RH or Beverley strain. These materials were stored in both of the refrigerating and the cold-storage rooms, then taken out of the rooms one after another at a short interval and examined on the existence of live Toxoplasma in them with the intraperitoneal inoculation into healthy mice. In the first experiment, it was revealed that the survival of the proliferative form of Toxoplasma in an infected mouse body was 8 days in the refrigerating room and 4 days in the cold-storage room, but a putrefactive sign was manifesting slowly in the mice stored more than 13 days in the refrigerating room and 6 days in the other. In the following experiment, the livers excised from RH-infected mice and the brains from Beverley-infected ones were stored only in the refrigerating room. It was recognized as the result that cysts were capable of survival for as long as 67 days and proliferative forms could survive for 11 days in the room. A control experiment was attempted on the resistance of T. gondii to -14â in a freezer and it was shown that both forms of this protozoa in the infected mouse organs could remain alive more than an hour but did not for 3 hours in a freezer of -14â. Temperatures in both rooms were continuously measured by auto-recording thermometers. In the refrigerating room, it was 0.47â in average and the cold-storage room always had 3 to 4â higher temperature than the refrigerating room.Toxoplasma gondiiã®äœæž©ã«å¯Ÿããæµææ§ã«ã€ããŠã®å ±åã¯å°ãªããªãããããããããã®ç 究ã§ã¯ãå®éšå®€å
ã®å·èµåº«ãŸãã¯ããªãŒã¶ãŒãªã©ã®ç²Ÿç¢ºã«èª¿ç¯ããã枩床æ¡ä»¶äžã«å®æœããããã®ã§ãããå± çèããã®å
èäžã«æœåšããæ¬åè«ãããã£ãšãéèŠãªæææºãšèŠãªãããŠããçŸåšã§ã¯ãå± å Žã®äœæž©å®€äžã§çèäžã®æ¬åè«ããã©ãçšã®æéçåãã€ã¥ããããç«åŠäžéèŠãªæå³ãæã€ããšã¯ãããŸã§ããªããäºå®ãå± å Žã®å·åŽå®€ãããã¯å·èµå®€ã®æž©åºŠã¯ãé »åã®æã®ééã倧éã®æž©ãã倧åç©èå¡ã®æ¬å
¥ãªã©ã®ãããçžåœãªå€åãåããããšãäºæž¬ãããå®éšå®€ã®å·èµåº«å
枩床æ¡ä»¶ãšã¯ããªãç°ãªããã®ã§ãããšèããããããæ¬ç 究ã¯ã以äžã®è¶£æšã«æ²¿ã£ãŠé·åŽåžå¶å± å Žå
ã®äœæž©å®€ãå©çšããT. gondiiã®å¢æ®åããã³ïŒåã®çåæéãæ€èšããã被æ€ææã¯ã倧åç©èå¡ãå
èãçšããããšãã§ããªãã£ãã®ã§ãRHããã³Beverleyæ ªææããŠã¹ããã³ãã®èåšã䜿çšãããã第1å®éšã§ã¯ãPHæ ªææããŠã¹èªäœãå·åŽå®€ããã³å·èµå®€ã«ä¿åããã以åŸãæ¯æ¥ãŸãã¯éæ¥ã«ä¿åããŠã¹äœãåãåºãããã®èããã³èŸä¹³å€ãå¥åžžããŠã¹è
¹è£å
æ¥çš®ãããã®ããŠã¹ããã®åè«æ€åºãè©Šã¿ããæ¥çš®ã30æ¥ä»¥å
ã«æ»äº¡ããããŠã¹ã¯å³æã«ããã以äžçåãããã®ã¯å± 殺ããŠããã®è
¹è£æ¶²ããã³è³äžã®åè«ã®æç¡ãé¡åŸ®é¡äžã«æ€èšããããã®æ瞟ã§ã¯ãããŠã¹äœå
ã®RHæ ªå¢æ®åã¯å·åŽå®€äžã§8æ¥éãå·èµå®€äžã§4æ¥éçåããããšãèªãããããããä¿åããŠã¹ã®è
¹è£å
èåšã®è
æãå·åŽå®€ã§ã¯13æ¥ã以éããããŸãå·èµå®€ã§ã¯6æ¥ãããèªããããããšããããã®æ瞟ã«ã¯ããŠã¹ã®è
æã圱é¿ãåãŒããŠããããšãæ³åããããå®éšäžã®å®€æž©ã¯ãå·åŽå®€ã§ã¯å¹³å0.9âãæé«2.5âãæäœ-1.1âãå·èµå®€ã§ã¯å¹³å4.2âãæé«äœå·Ÿã¯5.1ïœ3.2âã§ãã£ããã第2å®éšã§ã¯ãRHæ ªææããŠã¹èãšBeverleyæ ªææããŠã¹è³ãå·åŽå®€äžã«ä¿åããäžå®æéæ¯ã«åãåºããä¹³å€ãšããŠå¥åžžããŠã¹ã«æ¥çš®ãããæ¬å®éšã«ããããŠã¹èäžã®RHæ ªå¢æ®åã¯11æ¥éãããŠã¹ã®è³äžã®Beverleyæ ªååã¯å®ã«67æ¥éå·åŽå®€ã§çåããããšãå€æãããå®éšæéäžã®å·åŽå®€æž©åºŠã¯å¹³å0.47âãæé«äœå·Ÿã¯3.2ïœ-3.5âã«ãããã ã察ç
§å®éšãšããŠã-14âã®ããªãŒã¶ãŒã®äžã§ç¬¬2å®éšãšåäžææãçšããŠæ€æ»ãããããã®çµæãååãå¢æ®åãšãã1æéä¿åææäžã«çåããããšãèªãããã3æéææããã¯èšŒæã§ããªãã£ããã以äžã®å®éšã§ãå± å Žå·åŽå®€äžã§ååã¯67æ¥éãå¢æ®åã¯11æ¥éçåãããã€ãææåãä¿æããŠããããšãå€æãããã倧åç©èå¡ãèåšäžã§ã¯ãããé·æéçåããããšãæ³å®ããã